Significance of Hormone Receptor Status in Comparison of 18F -FDG-PET/CT and 99mTc-MDP Bone Scintigraphy for Evaluating Bone Metastases in Patients with Breast Cancer: Single Center Experience

Teke, Fatma; Teke, Memik; İnal, Ali; Kaplan, Muhammed Ali; Küçüköner, Mehmet; Aksu, Ramazan; Urakçı, Zuhat; Taşdemir, Bekir; Işıkdoğan, Abdurrahman

doi:10.7314/apjcp.2015.16.1.387

Cited by 13 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PET/CT was able to detect metastases at an early stage, even when there is no morphologic abnormality detected on CT; this may be due to PET detected the activity within the bone marrow with an absence of sufficient bone destruction. It was close to that found by Teke et al [11] who found a A Reconstructed whole body PET-MIP showed bilateral metabolically active breast masses, multiple variable sized metabolically active bilateral axillary lymph nodes, upper and lower paratracheal, prevascular, and bilateral hilar lymph nodes as well as multiple metabolic active bony lytic metastatic deposits at right scapula, head of the left humerus, sternum, multiple ribs, multiple vertebrae, both iliac and ischium bones right pubic, sacrum, and upper femuri. B1 Axial CT, B2 axial PET, and B3 axial hybrid PET/CT showed right breast metabolically active mass and multiple metabolically active bony lytic metastatic deposits.…”

Section: Discussionsupporting

confidence: 92%

The added value of hybrid 18F-FDG PET/CT over CT in the detection of breast cancer metastatic deposits

Abd-Elkader

Hassan

Omar

et al. 2020

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background: Breast cancer is a major health problem resulting in high morbidity and mortality. Early diagnosis of primary and secondary lesions is crucial to optimize treatment options. Our study aimed to investigate the role of PET-CT and CT alone in detecting metastatic lesions in breast cancer patients. Result: This retrospective study showed better PET diagnostic performance in the detection of lymph nodal and lytic bony metastatic deposits with more accurate detection of the malignant nature of hepatic focal lesions and detection of activity in sclerotic bony lesions, compared with CT alone, while CT had a higher value in the localization of lesions. Hybrid PET/CT showed optimal diagnostic performance than each modality separately. Conclusion: The combination of CT and PET was a powerful diagnostic tool that is more accurate than CT alone in the detection of distant metastases.

show abstract

Section: Discussionsupporting

confidence: 92%

The added value of hybrid 18F-FDG PET/CT over CT in the detection of breast cancer metastatic deposits

Abd-Elkader

Hassan

Omar

et al. 2020

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

show abstract

“…In addition to PET/CT detecting unsuspected distant metastases in 20 (22%) of 89 patients with stage III IDC, 6 (30%) of the 20 were upstaged by the 18 F-FDG PET component of the PET/CT study, without corresponding suggestive findings on CT or bone scanning. Our data support prior work suggesting that 18 F-FDG PET/CT may replace CT and bone scanning for some forms of breast cancer (22,23) and extends prior work by suggesting that this replacement may be favorable in patients with IDC but not necessarily in those with ILC.…”

Section: Discussionsupporting

confidence: 86%

Comparison of ¹⁸F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma

et al. 2015

View full text Add to dashboard Cite

Although guidelines such as those of the National Comprehensive Cancer Network consider 18F-FDG PET/CT for systemic staging of newly diagnosed stage III breast cancer patients, factors in addition to stage may influence the utility of PET/CT. Because invasive lobular carcinoma (ILC) is less conspicuous than invasive ductal carcinoma (IDC) on 18F-FDG PET, we hypothesized that tumor histology may be one such factor. We evaluated PET/CT systemic staging of patients newly diagnosed with ILC compared with IDC. Methods In this Institutional Review Board–approved retrospective study, our Hospital Information System was screened for ILC patients who underwent PET/CT in 2006–2013 before systemic or radiation therapy. Initial stage was determined from examination, mammography, ultrasound, MR, or surgery. PET/CT was performed to identify unsuspected distant metastases. A sequential cohort of stage III IDC patients was evaluated for comparison. Upstaging rates were compared using the Pearson χ2 test. Results The study criteria were fulfilled by 146 ILC patients. PET/CT revealed unsuspected distant metastases in 12 (8%): 0 of 8 with initial stage I, 2 of 50 (4%) stage II, and 10 of 88 (11%) stage III. Upstaging to IV by PET/CT was confirmed by biopsy in all cases. Three of 12 upstaged patients were upstaged only by the CT component of the PET/CT, as the metastases were not 18F-FDG–avid. In the comparison stage III IDC cohort, 22% (20/89) of patients were upstaged to IV by PET/CT. All 20 demonstrated 18F-FDG–avid metastases. The relative risk of PET/CT revealing unsuspected distant metastases in stage III IDC patients was 1.98 times (95% confidence interval, 0.98–3.98) that of stage III ILC patients (P = 0.049). For 18F-FDG–avid metastases, the relative risk of PET/CT revealing unsuspected 18F-FDG–avid distant metastases in stage III IDC patients was 2.82 times (95% confidence interval, 1.26–6.34) that of stage III ILC patients (P = 0.007). Conclusion 18F-FDG PET/CT was more likely to reveal unsuspected distant metastases in stage III IDC patients than in stage III ILC patients. In addition, some ILC patients were upstaged by non–18F-FDG-avid lesions visible only on the CT images. Overall, the impact of PET/CT on systemic staging may be lower for ILC patients than for IDC patients.

show abstract

Section: Possibilities Of Positron Emission Tomography In the Metastaunclassified

“…Приблизительно у 30% пациенток с впервые выяв-ленным РМЖ отмечают распространение опухо-ли в регионарные лимфатические узлы, 5-летняя выживаемость этой группы больных составляет 84,4%. 5% больных с впервые выявленным РМЖ имеют метастатическую форму РМЖ с 5-летней выживаемостью 24,3% [26,35].Известно, что определённые типы опухолей, в частности РМЖ или рак предстательной железы, характеризуются повышенной частотой метаста-зирования в кости скелета. При этом метастазы могут развиваться через много лет после развития первичной опухоли, значительно снижая качес-…”

unclassified

“…В настоящее время считают, что ФДГ-ПЭТ служит надёжным методом оценки распростра-нённости процесса на поздних стадиях РМЖ у пациентов, подвергающихся химиотерапии [25, 35,36]. Кроме того, применение ФДГ-ПЭТ/КТ позволяет определять не выявленные ранее ре-гионарные метастазы в лимфатических узлах за пределами подмышечной области [2,8].…”

unclassified

See 1 more Smart Citation

Possibilities of positron emission tomography in the metastatic breast cancer diagnosis

2016

View full text Add to dashboard Cite

Кировская государственная медицинская академия, г. Киров, Россия Статья поступила 28.05.2015; принята к печати 04.08.2015. Реферат DOI: 10.17750/KMJ2016-262 Выполнен анализ литературных данных о возможностях применения метода позитронно-эмиссионной томо-графии в комплексе лечебно-диагностических мероприятий при метастатическом раке молочной железы. Описа-ны возможности и приведены характеристики метода по данным ряда исследований, в частности в отношении выявления метастазов различной локализации. Указано, что по сравнению с обычными методами визуализации позитронно-эмиссионная томография служит более чувствительным и специфичным методом диагностики от-далённых метастазов. Приведены результаты клинических исследований по оценке возможностей применения метода в выявлении метастазов рака молочной железы в лимфатических узлах, различных органах, а также костных метастазов. Показано, что внедрение в практику натрия фторида позволило применять этот препарат как биомаркёр костной ткани, который может быть использован при выполнении позитронно-эмиссионной то-мографии. Приведены данные о том, что одновременное применение позитронно-эмиссионной томографии с 18 F-фтордезоксиглюкозой и компьютерной томографии обладает высокой диагностической ценностью в отноше-нии выявления отдалённых метастазов при раке молочной железы. Рассмотрены возможности метода по выяв-лению различных форм первичного инвазивного рака молочной железы, в том числе инвазивного протокового и долькового рака. Выполнен анализ перспектив дальнейшего увеличения возможностей применения позитронно-эмиссионной томографии, в частности рассмотрены сообщения о возможности так называемого гибридного ска-нирования с помощью позитронно-эмиссионной томографии и магнитно-резонансной томографии. Подчёркнуто, что важнейшей задачей использования метода в клинической практике в перспективе может стать мониториро-вание местно-регионарных рецидивов и отдалённых метастазов после первичного лечения рака молочной железы.Ключевые слова: рак молочной железы, позитронно-эмиссионная томография, метастазы, сцинтиграфия костей скелета. POSSIBILITIES OF POSITRON EMISSION TOMOGRAPHY IN THE METASTATIC BREAST CANCER DIAGNOSISM.S. Ramazanova, A.G. Kislichko, E.A. Glushkov Kirov State Medical Academy, Kirov, Russia An analysis of published data on the possibilities of the positron emission tomography method application in complex diagnostic and treatment activities in metastatic breast cancer was performed. The possibilities are described and the method characteristics according to series of studies, in particular with regard to the various localization metastases identification are given. It is noted that, compared with conventional imaging techniques, positron emission tomography is more sensitive and specific method of distant metastases diagnosis. The results of clinical studies on assessment of the method application possibilities in the detection of breast cancer metastases in lymph nodes, various organs and bone metastases are given. It has been shown that the introduction of so...

show abstract

Significance of Hormone Receptor Status in Comparison of 18F -FDG-PET/CT and 99mTc-MDP Bone Scintigraphy for Evaluating Bone Metastases in Patients with Breast Cancer: Single Center Experience

Cited by 13 publications

References 20 publications

The added value of hybrid 18F-FDG PET/CT over CT in the detection of breast cancer metastatic deposits

The added value of hybrid 18F-FDG PET/CT over CT in the detection of breast cancer metastatic deposits

Comparison of ¹⁸F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma

Possibilities of positron emission tomography in the metastatic breast cancer diagnosis

Contact Info

Product

Resources

About

Significance of Hormone Receptor Status in Comparison of 18F -FDG-PET/CT and 99mTc-MDP Bone Scintigraphy for Evaluating Bone Metastases in Patients with Breast Cancer: Single Center Experience

Cited by 13 publications

References 20 publications

The added value of hybrid 18F-FDG PET/CT over CT in the detection of breast cancer metastatic deposits

The added value of hybrid 18F-FDG PET/CT over CT in the detection of breast cancer metastatic deposits

Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma

Possibilities of positron emission tomography in the metastatic breast cancer diagnosis

Contact Info

Product

Resources

About

Comparison of ¹⁸F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma